141 related articles for article (PubMed ID: 37082098)
1. Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer.
Feliciano JL; McLoone D; Xu Y; Quek RGW; Kuznik A; Pouliot JF; Gullo G; Rietschel P; Guyot P; Konidaris G; Chan K; Keeping S; Wilson FR; Freemantle N
Front Oncol; 2022; 12():1081729. PubMed ID: 37082098
[TBL] [Abstract][Full Text] [Related]
2. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
Sezer A; Kilickap S; Gümüş M; Bondarenko I; Özgüroğlu M; Gogishvili M; Turk HM; Cicin I; Bentsion D; Gladkov O; Clingan P; Sriuranpong V; Rizvi N; Gao B; Li S; Lee S; McGuire K; Chen CI; Makharadze T; Paydas S; Nechaeva M; Seebach F; Weinreich DM; Yancopoulos GD; Gullo G; Lowy I; Rietschel P
Lancet; 2021 Feb; 397(10274):592-604. PubMed ID: 33581821
[TBL] [Abstract][Full Text] [Related]
3. Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial.
Makharadze T; Gogishvili M; Melkadze T; Baramidze A; Giorgadze D; Penkov K; Laktionov K; Nemsadze G; Nechaeva M; Rozhkova I; Kalinka E; Li S; Li Y; Kaul M; Quek RGW; Pouliot JF; Seebach F; Lowy I; Gullo G; Rietschel P
J Thorac Oncol; 2023 Jun; 18(6):755-768. PubMed ID: 37001859
[TBL] [Abstract][Full Text] [Related]
4. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial.
Gogishvili M; Melkadze T; Makharadze T; Giorgadze D; Dvorkin M; Penkov K; Laktionov K; Nemsadze G; Nechaeva M; Rozhkova I; Kalinka E; Gessner C; Moreno-Jaime B; Passalacqua R; Li S; McGuire K; Kaul M; Paccaly A; Quek RGW; Gao B; Seebach F; Weinreich DM; Yancopoulos GD; Lowy I; Gullo G; Rietschel P
Nat Med; 2022 Nov; 28(11):2374-2380. PubMed ID: 36008722
[TBL] [Abstract][Full Text] [Related]
5. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Vandormael K; Riccio A; Yang J; Pietanza MC; Brahmer JR
J Clin Oncol; 2019 Mar; 37(7):537-546. PubMed ID: 30620668
[TBL] [Abstract][Full Text] [Related]
6. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial.
Baramidze A; Makharadze T; Gogishvili M; Melkadze T; Giorgadze D; Penkov K; Laktionov K; Nemsadze G; Nechaeva M; Rozhkova I; Kalinka E; Ag McIntyre D; Perez J; Kaul M; Quek RGW; Seebach F; Rietschel P; Pouliot JF
Lung Cancer; 2024 May; 193():107821. PubMed ID: 38820979
[TBL] [Abstract][Full Text] [Related]
7. Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-Lung 3.
Makharadze T; Quek RGW; Melkadze T; Gogishvili M; Ivanescu C; Giorgadze D; Dvorkin M; Penkov K; Laktionov K; Nemsadze G; Nechaeva M; Rozhkova I; Kalinka E; Gessner C; Moreno-Jaime B; Passalacqua R; Konidaris G; Rietschel P; Gullo G
Cancer; 2023 Jul; 129(14):2256-2265. PubMed ID: 37151113
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study.
Gümüş M; Chen CI; Ivanescu C; Kilickap S; Bondarenko I; Özgüroğlu M; Gogishvili M; Turk HM; Cicin I; Harnett J; Mastey V; Naumann U; Reaney M; Konidaris G; Sasane M; Brady KJS; Li S; Gullo G; Rietschel P; Sezer A
Cancer; 2023 Jan; 129(1):118-129. PubMed ID: 36308296
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50.
Kuznik A; Smare C; Chen CI; Venkatachalam M; Keeping S; Atsou K; Xu Y; Wilson F; Guyot P; Chan K; Glowienka E; Konidaris G
Value Health; 2022 Feb; 25(2):203-214. PubMed ID: 35094793
[TBL] [Abstract][Full Text] [Related]
10. Survival with Cemiplimab in Recurrent Cervical Cancer.
Tewari KS; Monk BJ; Vergote I; Miller A; de Melo AC; Kim HS; Kim YM; Lisyanskaya A; Samouëlian V; Lorusso D; Damian F; Chang CL; Gotovkin EA; Takahashi S; Ramone D; Pikiel J; Maćkowiak-Matejczyk B; Guerra Alía EM; Colombo N; Makarova Y; Rischin D; Lheureux S; Hasegawa K; Fujiwara K; Li J; Jamil S; Jankovic V; Chen CI; Seebach F; Weinreich DM; Yancopoulos GD; Lowy I; Mathias M; Fury MG; Oaknin A;
N Engl J Med; 2022 Feb; 386(6):544-555. PubMed ID: 35139273
[TBL] [Abstract][Full Text] [Related]
11. Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50.
Freemantle N; Xu Y; Wilson FR; Guyot P; Chen CI; Keeping S; Konidaris G; Chan K; Kuznik A; Atsou K; Glowienka E; Pouliot JF; Gullo G; Rietschel P
Ther Adv Med Oncol; 2022; 14():17588359221105024. PubMed ID: 35747163
[TBL] [Abstract][Full Text] [Related]
12. First-line Cemiplimab versus Standard Chemotherapy in Advanced Non-small Cell Lung Cancer Patients with at Least 50% Programmed Cell Death Receptor Ligand-1 Positivity: Analysis of Cost-effectiveness.
Zhang M; Liu X; Wen F; Wu Q; Zhou K; Bai L; Li Q
Clin Oncol (R Coll Radiol); 2022 Mar; 34(3):e123-e129. PubMed ID: 34736841
[TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
14. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
15. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
Sternberg CN; Hawkins RE; Wagstaff J; Salman P; Mardiak J; Barrios CH; Zarba JJ; Gladkov OA; Lee E; Szczylik C; McCann L; Rubin SD; Chen M; Davis ID
Eur J Cancer; 2013 Apr; 49(6):1287-96. PubMed ID: 23321547
[TBL] [Abstract][Full Text] [Related]
16. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
17. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.
Papadimitrakopoulou VA; Mok TS; Han JY; Ahn MJ; Delmonte A; Ramalingam SS; Kim SW; Shepherd FA; Laskin J; He Y; Akamatsu H; Theelen WSME; Su WC; John T; Sebastian M; Mann H; Miranda M; Laus G; Rukazenkov Y; Wu YL
Ann Oncol; 2020 Nov; 31(11):1536-1544. PubMed ID: 32861806
[TBL] [Abstract][Full Text] [Related]
18. FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC.
Akinboro O; Larkins E; Pai-Scherf LH; Mathieu LN; Ren Y; Cheng J; Fiero MH; Fu W; Bi Y; Kalavar S; Jafri S; Mishra-Kalyani PS; Fourie Zirkelbach J; Li H; Zhao H; He K; Helms WS; Chuk MK; Wang M; Bulatao I; Herz J; Osborn BL; Xu Y; Liu J; Gong Y; Sickafuse S; Cohen R; Donoghue M; Pazdur R; Beaver JA; Singh H
Clin Cancer Res; 2022 Jun; 28(11):2221-2228. PubMed ID: 35101885
[TBL] [Abstract][Full Text] [Related]
19. Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.
Solomon BJ; Kim DW; Wu YL; Nakagawa K; Mekhail T; Felip E; Cappuzzo F; Paolini J; Usari T; Tang Y; Wilner KD; Blackhall F; Mok TS
J Clin Oncol; 2018 Aug; 36(22):2251-2258. PubMed ID: 29768118
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50.
Wang L; Peng Y; Zeng X; Peng L; Li S; Qin S; Wan X; Tan C
Adv Ther; 2021 Aug; 38(8):4354-4365. PubMed ID: 34241780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
